Drugs without side effects: Researchers explore novel ways to classify proteins

April 26, 2013 by Jessica Blackburn & Will Ferguson
Drugs without side effects:  Researchers explore novel ways to classify proteins
Graduate student Janelle Leuthaeuser (left) and Jacque Fetrow, Reynolds Professor of Computational Biophysics and Dean of the College, talk about their research.

Janelle Leuthaeuser is on the cutting edge of biophysics. A molecular genetics and genomics Ph.D. student, she is part of a nationwide effort to create a more efficient generation of protein-based drugs.

Proteins are the of cells. They get rid of waste, transmit cellular signals and carry out the that keep our bodies running. The biomolecules' role as intracellular regulators and their sheer number (there are about 7,000 different types of in a typical human body cell) also make them one of the most frequent targets of drugs.

Drugs can help your body fight off disease and infection by speeding up or altering the chemical reactions regulated by proteins. Around half of the drugs currently on the market work by targeting proteins.

Researchers have identified millions of proteins and are discovering new ones faster than ever before. The problem, when it comes to making new and better drugs, is that two proteins can have a similar structure or but react very differently to the same . This can lead to adverse drug side effects that range from mildly discomforting to potentially life-threatening. In fact, more than three million serious to occur every year. There are more than 100,000 deaths from these reactions per year, placing prescription drug use as the fourth leading cause of death in the United States, ahead of , diabetes, AIDS and pneumonia.

"The more information we can get about how specific proteins function the better we can target them with drugs," Leuthaeuser said. "We have the technology to identify a lot of new proteins now, but not to efficiently identify the details of their molecular function."

She is working with Jacquelyn Fetrow, Reynolds Professor of Computational Biophysics and Dean of the College, and a national team of researchers to develop an automated program that classifies different proteins by their active site, the location where chemical reactions occur. Contemporary technologies predict function based on the full sequence or structure of protein molecules. The Wake Forest led team found this method often vaguely or incorrectly classifies proteins. Leuthaeuser said that proteins can be grouped together by function more accurately when using the sequence and structure directly surrounding the active site rather than the overall structure of a protein molecule.

"When proteins have less than 30-40 percent sequence identity, it is more helpful to look at just the active sites," Leuthaeuser said. "We can more accurately predict their function when we are looking at this small area."

A simple example of how the active site information can be applied in developing more efficient drugs is with aspirin. Leuthaeuser said aspirin affects two similar proteins – COX 1 and COX 2 – that do two very different things. COX 2 is involved with general pain and inflammation while COX 1 regulates swelling in the gastrointestinal tract. Aspirin inhibits both COX 1 and COX 2.

"This is why taking aspirin can give you an upset stomach," Leuthaeuser said. "We would like to inhibit just COX 2 and not COX 1. "There are differences in the active sites of COX 1 and COX 2 that allow drugs to be targeted to COX 2 selectively, decreasing the potential gastrointestinal side effects."

Leuthaeuser is in the process of characterizing active site information for a group of structurally diverse proteins using a computer program developed by members of the Fetrow Lab. While the project is in an early testing and validation stage, she said the eventual hope is that utilizing profiling technology will enable accurate and efficient protein function prediction. This could in turn assist pharmaceutical researchers in designing drugs with fewer adverse effects.

Patsy Babbitt, a professor of Pharmaceutical Chemistry at the University of California, San Francisco, has been working with Fetrow on models to predict protein function for five years and is a collaborator on the project. She said automated systems like this will not only make it easier to develop drugs with fewer side effects but will greatly speed up the process of development in general. Until recently, Babbitt said the only way to efficiently and accurately identify at the necessary level of molecular detail was to examine them one by one in the lab, a painstakingly slow process that requires a significant amount of time for each protein and costs a significant amount of money.

She said the goal is to bring the time down from a few years to a few weeks.

"The precision will not be as good as individual experiments," Babbitt, said. "But, it will take much less time and money to build an infrastructure to help other scientists form hypotheses and identify the details of protein functional sites."

Explore further: Researchers use new approach to predict protein function

Related Stories

Researchers use new approach to predict protein function

July 11, 2007

In a paper published online this month in the journal Nature Chemical Biology, researchers report that they have developed a way to determine the function of some of the hundreds of thousands of proteins for which amino acid ...

More fish oil, less vegetable oil, better for your health

July 26, 2007

Scientists have provided new evidence that using more fish oil than vegetable oil in the diet decreases the formation of chemicals called prostanoids, which, when produced in excess, increase inflammation in various tissues ...

New study may explain Vioxx side-effects

August 27, 2007

Vioxx and related pain medications were taken off the market in 2004 because they caused dangerous heart problems in some people. A group of scientists, led by Timothy Hla at the University of Connecticut, may now have figured ...

‘Designer molecules’ being developed to fight disease

June 12, 2009

(PhysOrg.com) -- Researchers in the Department of Cardiovascular Sciences at the University of Leicester are developing a new way to make protein based drugs with potential applications in stroke, vascular inflammation, blood ...

New protein structure model to inhibit cancer

July 29, 2011

Researchers at the University of Hertfordshire have developed a new structural model of a protein, which makes it possible to develop more effective drugs to target diseases such as cancer, heart disease and influenza.

Recommended for you

Basic research fuels advanced discovery

August 26, 2016

Clinical trials and translational medicine have certainly given people hope and rapid pathways to cures for some of mankind's most troublesome diseases, but now is not the time to overlook the power of basic research, says ...

New avenue for understanding cause of common diseases

August 25, 2016

A ground-breaking Auckland study could lead to discoveries about many common diseases such as diabetes, cancer and dementia. The new finding could also illuminate the broader role of the enigmatic mitochondria in human development.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.